REHOVOT, Israel--(BUSINESS WIRE)--March 9, 2006--Kamada (TASE: KMDA), a bio-pharmaceutical company which develops, manufactures and markets prescription drugs, today announced the crossing of a major milestone on its API roadmap with the FDA (Food and Drug Administration) announcing the removal of the “Clinical Hold” status. This announcement marks the final approval required by the company to start the third phase of clinical trials with Kamada’s flagship drug, Alpha 1-Proteinase Inhibitor (API). The clinical trial will include 50 patients from the USA and will follow the protocol submitted to and approved by the FDA.
